Stock Events

Stock Events

Enzymatica 

€0.24
2
-€0.02-6.51% Thursday 06:04

Statistics

Day High
0.24
Day Low
0.24
52W High
0.4
52W Low
0.12
Volume
-
Avg. Volume
-
Mkt Cap
59.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

23AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.08
-0.06
-0.05
-0.03
Expected EPS
N/A
Actual EPS
N/A

Financials

-100.85%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
13.19MRevenue
-13.3MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EN9.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, a large pharmaceutical company, competes in the production of various healthcare products, including those for respiratory diseases, potentially overlapping with Enzymatica's cold prevention products.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson offers a broad range of health products, including treatments for respiratory conditions, directly competing with Enzymatica's cold remedies.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is involved in the development and manufacturing of healthcare products, including those for respiratory health, competing with Enzymatica's enzyme-based treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis produces healthcare products that address a myriad of conditions, including respiratory diseases, which places them in competition with Enzymatica.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories manufactures medical devices and healthcare products that can compete with Enzymatica's offerings in the general health and wellness sector.
Merck
MRK
Mkt Cap214.76B
Merck & Co., known for its wide range of pharmaceutical products, competes in the area of respiratory health treatments, relevant to Enzymatica's market.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG engages in the pharmaceutical and diagnostics business, including areas that overlap with Enzymatica's focus on respiratory and immune health.
Sanofi
SNY
Mkt Cap124.45B
Sanofi operates globally in pharmaceuticals, including treatments for respiratory conditions, competing with Enzymatica's product range.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca specializes in several major health areas, including respiratory diseases, making it a competitor to Enzymatica's enzyme-based health products.

About

Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of illness. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; ViruProtect name in Austria and Belgium; ColdGuard name in South Africa; Zerinol Virus Defense in Italy; and Psysiomer Stop Virus in France. It also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden.
Show more...
CEO
Employees
26
Country
SE
ISIN
SE0003943620
WKN
000A1WZEV

Listings

ST
SE
ENZY.ST
F
DE
EN9.F

0 Comments

Share your thoughts

FAQ

What is Enzymatica stock price today?▼
The current price of EN9.F is €0.24 EUR — it has decreased by -6.51% in the past 24 hours. Watch Enzymatica stock price performance more closely on the chart.
What is Enzymatica stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enzymatica stocks are traded under the ticker EN9.F.
Is Enzymatica stock price growing?▼
EN9.F stock has risen by +22.61% compared to the previous week, the month change is a +58.96% rise, over the last year Enzymatica has showed a -29.89% decrease.
What is Enzymatica market cap?▼
Today Enzymatica has the market capitalization of 59.23M
When is the next Enzymatica earnings date?▼
Enzymatica is going to release the next earnings report on April 23, 2026.
What were Enzymatica earnings last quarter?▼
EN9.F earnings for the last quarter are -0 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Enzymatica revenue for the last year?▼
Enzymatica revenue for the last year amounts to 13.19M EUR.
What is Enzymatica net income for the last year?▼
EN9.F net income for the last year is -13.3M EUR.
How many employees does Enzymatica have?▼
As of April 03, 2026, the company has 26 employees.
In which sector is Enzymatica located?▼
Enzymatica operates in the Health Care sector.
When did Enzymatica complete a stock split?▼
Enzymatica has not had any recent stock splits.